Drug firm Sun Pharmaceutical Industries today said it has received final approval from the US health regulator for its generic testosterone cypionate injection indicated for treatment of testosterone hormone deficiency.

"The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP," Sun Pharma said in a statement.

The approval is for the product in the strengths of 100 mg/ml and 200mg/ml, it added.